Evidence map›Paper›PMID 30675231›Full record

ArticleOncology letters2019

Expression and selective activation of somatostatin receptor subtypes induces cell cycle arrest in cancer cells.

Yi Zou, Haiping Tan, Yuanfeng Zhao, Yuan Zhou, Lin Cao

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 30 citations in OpenAlex.

  1. Efficacy ofCurrent oncology (Toronto, Ont.) · 2020
    Trial
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Review
  8. Somatostatin and Somatostatin Receptors in Tumour Biology.International journal of molecular sciences · 2023
    Review
  9. Article
  10. Imaging and treatment withBJR case reports · 2023
    Article
  11. Theranostics in breast cancer.Frontiers in nuclear medicine · 2023
    Review
  12. Review
  13. Review
  14. Role of Somatostatin Signalling in Neuroendocrine Tumours.International journal of molecular sciences · 2022
    Review
  15. Promoter Specific Methylation ofFrontiers in genetics · 2022
    Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Yi ZouDepartment of Biology, School of Life Science and Technology, Jinan University, Guangzhou, Guangdong 510632, P.R. China.
Haiping TanDepartment of Biology, School of Life Science and Technology, Jinan University, Guangzhou, Guangdong 510632, P.R. China.
Yuanfeng ZhaoDepartment of Biology, School of Life Science and Technology, Jinan University, Guangzhou, Guangdong 510632, P.R. China.
Yuan ZhouDepartment of Biology, School of Life Science and Technology, Jinan University, Guangzhou, Guangdong 510632, P.R. China.
Lin CaoDepartment of Anesthesiology of Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong 510120, P.R. China.
Jinan University · CNSun Yat-sen Memorial Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Somatostatin receptors (SSTRs) are G-protein-coupled plasma membrane receptors that have been determined to be expressed in normal and cancer tissues. Activation of SSTRs frequently results in inhibition of cell proliferation and therefore somatostatin analogues (SSAs) have been used in cancer treatment. However, the variable outcomes of SSA treatment were considered to be the consequences of loss-of-expression of SSTRs and/or subtype-specific effects. In the present study, the patterns of SSTR expression in 160 breast cancer tissues were investigated, and the mechanisms of SSTR activation and the influence on cell proliferation were further characterized. The expression levels of SSTR1-5 were determined using immunohistology. Hemagglutinin-SSTR1 and MYC-SSTR4 were transiently overexpressed in MDA-MB-435S cells, and the potential receptor dimerization was determined using immunofluorescence and co-immunoprecipitation. The influence of SSTR1 and SSTR4 expression/activation on cell proliferation was monitored using flow cytometry. The results demonstrated that all five SSTR subtypes were expressed at variable levels in tumor tissues, with the highest positive expression instance being determined for SSTR1 and SSTR4, with positive expression levels in 90.0 and 71.3% of tumor tissues, respectively. Immunofluorescence and co-immunoprecipitation revealed SSTR1/SSTR4 heterodimerization, which was increased in response to receptor activation using the subtype-specific SSA L-803087. The translocation of SSTR1/SSTR4 dimers into the cytoplasm upon receptor activation was also observed. Additionally, it was identified using flow cytometry that co-expression and activation of SSTR1 and SSTR4 in MDA-MB-435S cells resulted in a decreased proportion of S-phase cells. The results of the present study revealed that SSTR1 and SSTR4 are the most frequently expressed SSTR subtypes in breast cancer, and that the cell cycle arrest was mediated by SSTR1/SSTR4 dimerization/activation.

Indexed as

breast cancercell cycle arrestreceptor dimerizationsomatostatin analoguessomatostatin receptor

Identifiers

PMID30675231
PMCPMC6341781
OpenAlexW2903515165

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.